Dublin, Dec. 05, 2019 (GLOBE NEWSWIRE) -- The "Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2019: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals.

The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 250 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report Scope

• Trends in infectious vaccines dealmaking in the biopharma industry since 2014
• Analysis of infectious vaccines deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 290 infectious vaccines deal records
• Identify the most active infectious vaccine dealmakers since 2014
• The leading infectious vaccines deals by value since 2014
• Includes adjuvant deals and alliances since 2014

Available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific infectious therapy target
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Infectious Vaccines deals by company A-Z

Appendix 2 - Infectious Vaccines deals by stage of development

• Discovery
• Preclinical
• Phase I
• Phase II
• Phase III
• Regulatory
• Marketed
• Formulation

Appendix 3 - Infectious Vaccines deals by deal type

• Asset purchase
• Assignment
• Bigpharma outlicensing
• Co-development
• Collaborative R&D
• Co-market
• Co-promotion
• CRADA
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Settlement
• Spin out
• Sub-license
• Supply
• Technology transfer
• Termination

Appendix 4 - Infectious Vaccines deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/p3e7df

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900